Why PF-05175157 Remains a Reference Dual ACC Inhibitor in Metabolic Disease Research

Acetyl-CoA carboxylase sits at a genuine fork in fat metabolism: its product, malonyl-CoA, is both the building block for new fatty acid synthesis and the molecule that blocks fat from entering mitochondria to be burned. Because ACC1 and ACC2 share nearly identical catalytic domains, building a selective inhibitor for just one isoform is difficult – and a compound that blocks only one leaves the other pathway free to compensate, which muddies any interpretation of the resulting phenotype.

What makes it useful in practice

Among tool compounds addressing that problem, PF-05175157 is one of the more consistently referenced dual ACC1/ACC2 inhibitors. It blocks human ACC1 and ACC2 with IC50 values of 27 nM and 33 nM, and the rat orthologs at 23.5 nM and 50.4 nM – a narrow enough gap across species that biochemical data from rodent assays can be read alongside human enzyme data without heavy correction. That cross-species consistency is a meaningful practical advantage when translating in vitro findings toward animal efficacy studies.

Why dual inhibition changes the biology

Blocking both isoforms at once produces a coordinated shift rather than a partial one: lipogenic output drops in the liver while fatty acid entry into muscle mitochondria accelerates, since the mitochondrial import brake normally imposed by malonyl-CoA is lifted at the same time. In lean rats, a single oral dose measurably lowered malonyl-CoA in both liver and skeletal muscle within an hour, with whole-body respiratory exchange ratio shifting toward greater fat use – a functional readout that ties enzyme inhibition directly to a systemic metabolic outcome.

Why the clinical and off-target data matter

PF-05175157 reached oral bioavailability of roughly 40 percent in rats and 54 percent in dogs, and advanced into human trials for type 2 diabetes, where it suppressed de novo lipogenesis and increased whole-body fatty acid oxidation, mirroring the rodent mechanism. Development was ultimately discontinued after a reduction in platelet count emerged, traced to ACC inhibition within bone marrow progenitor cells rather than an off-target effect – a finding that itself became useful for understanding ACC’s role outside lipid metabolism. Separately, in flavivirus-infected mice, the compound reduced viral load in serum and kidney tissue, since flavivirus replication depends heavily on host lipid synthesis machinery.

Why tool compounds with documented profiles still lead the way

Few dual ACC inhibitors combine matched potency across isoforms and species with confirmed in vivo target engagement and human pharmacodynamic data. For researchers benchmarking new lipogenesis inhibitors, modeling metabolic disease, or probing the lipid dependencies of viral replication or tumor growth, that depth of characterization is what makes the comparison worth making.